Efficacy of Shanvac-B recombinant DNA hepatitis B vaccine in health care workers of Northern India

Hepatobiliary and Pancreatic Diseases International

Volumn 9, Issue 4, 2010, Pages 393-397

  Thakur, Varsha ^a   Pati, Nirupma T ^a   Gupta, Rajkumar C ^a   Sarin, Shiv K ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

Health care workers; Hepatitis B virus; Hepatitis C virus; Immunogenicity; Seroprotection; Shanvac B

Indexed keywords

RECOMBINANT HEPATITIS B VACCINE; VIRUS DNA;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODYACHE; CIGARETTE SMOKING; COUGHING; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; FEVER; HEALTH CARE PERSONNEL; HEPATITIS B; HUMAN; HYPERTENSION; INDIA; INJECTION SITE EDEMA; INJECTION SITE PAIN; INJECTION SITE RASH; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PROPHYLAXIS; SCREENING TEST; SKIN REDNESS; VIRUS TITRATION; VOMITING;

ADOLESCENT; ADULT; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; INDIA; INFECTIOUS DISEASE TRANSMISSION, PROFESSIONAL-TO-PATIENT; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VACCINES, DNA; YOUNG ADULT;

EID: 77955594330     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Fay OH. Hepatitis B in Latin America: epidemiological patterns and eradication strategy. The Latin American Regional Study Group. Vaccine 1990;8:S100-106; discussion S134-139.
2. Sarin SK, Guptan RC, Banerjee K, Khandekar P. Low prevalence of hepatitis C viral infection in patients with nonalcoholic chronic liver disease in India. J Assoc Physicians India 1996;44:243-245.
3. Thyagarajan SP, Jayaram S, Mohanavalli B. Prevalence of HBV in the general population of India. In: Sarin SK, Singhal AK, editors. Hepatitis B in India: Problems and Prevention, New Delhi, CBS Publishers;1996:5-16.
4. Ganju SA, Goel A. Prevalence of HBV and HCV infection among health care workers (HCWs). J Commun Dis 2000; 32:228-230.
5. Hazra BR, Saha SK, Mazumder AK, Deb A, Sinha S. Incidence of hepatitis B virus (HBV) infection amongst clinically diagnosed acute viral hepatitis cases and relative risk of development of HBV infection in high risk groups in Calcutta. Indian J Public Health 1998;42:56-58.
6. Shiao J, Guo L, McLaws ML. Estimation of the risk of bloodborne pathogens to health care workers after a needlestick injury in Taiwan. Am J Infect Control 2002;30: 15-20.
7. Kosgeroglu N, Ayranci U, Vardareli E, Dincer S. Occupational exposure to hepatitis infection among Turkish nurses: frequency of needle exposure, sharps injuries and vaccination. Epidemiol Infect 2004;132:27-33.
8. Panlilio AL, Shapiro CN, Schable CA, Mendelson MH, Montecalvo MA, Kunches LM, et al. Serosurvey of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among hospital-based surgeons. Serosurvey Study Group. J Am Coll Surg 1995;180:16-24.
9. Petrosillo N, Puro V, Ippolito G, Di Nardo V, Albertoni F, Chiaretti B, et al. Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in health care workers: a multiple regression analysis of risk factors. J Hosp Infect 1995;30:273-281.
10. Hakre S, Reyes L, Bryan JP, Cruess D. Prevalence of hepatitis B virus among health care workers in Belize, Central America. Am J Trop Med Hyg 1995;53:118-122.
11. Mulley AG, Silverstein MD, Dienstag JL. Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. N Engl J Med 1982;307:644-652.
12. No authors listed. Recommendations for preventing transmission of human immunodeficiency virus and hepatitis B virus to patients during exposure-prone invasive procedures. AORN J 1991;54:576-582.
13. Ferraz ML, de Oliveira PM, Figueiredo VM, Kemp VL, Castelo Filho A, Silva AE. The optimization of the use of economic resources for vaccination against hepatitis B in professionals in the health area. Rev Soc Bras Med Trop 1995;28:393-403.
14. Palmovic D, Crnjakovic-Palmovic J. Vaccination against hepatitis B: results of the analysis of 2000 population members in Croatia. Eur J Epidemiol 1994;10:541-547.
15. Abraham P, Mistry FP, Bapat MR, Sharma G, Reddy GR, Prasad KS, et al. Evaluation of a new recombinant DNA hepatitis B vaccine (Shanvac-B). Vaccine 1999;17:1125-1129.
16. Karpuch J, Scapa E, Eshchar J, Waron M, Bar-Shany S, Shwartz T. Vaccination against hepatitis B in a general hospital in Israel: antibody level before vaccination and immunogenicity of vaccine. Isr J Med Sci 1993;29:449-452.
17. Thakur V, Guptan RC, Basir SF, Parvez MK, Sarin SK. Enhanced immunogenicity of recombinant hepatitis B vaccine in exposed family contacts of chronic liver disease patients. Scand J Infect Dis 2001;33:618-621.
18. Mahoney FJ, Stewart K, Hu H, Colemn P, Alter MJ. Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. Arch Intern Med 1997;157:2601-2605.
19. Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 1990;263:1218-1222.
20. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998;15:1-8.
21. Oliveira PM, Silva AE, Kemp VL, Juliano Y, Ferraz ML. Comparison of three different schedules of vaccination against hepatitis B in health care workers. Vaccine 1995;13: 791-794.
22. Dienstag JL, Werner BG, Polk BF, Snydman DR, Craven DE, Platt R, et al. Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med 1984;101:34-40.